LA JOLLA

LIMITED

11 October 2006

Dr. Daniel Brasseur
CHMP Chairman, EMEA
7 Westferry Circus
Canary Wharf
LONDON
E14 4HB
United Kingdom



Subject: Withdrawal of Riquent® (abetimus sodium), 100 mg, solution for injection
EMEA/H/C/000733

Dear Dr. Brasseur,

I would like to inform you that, at this point in time, La Jolla Limited, a wholly owned subsidiary of La Jolla Pharmaceutical Company (LJP), has taken the decision to withdraw the application for Marketing Authorisation of Riquent® (abetimus sodium), 100 mg, solution for injection.

Riquent is intended for the treatment of lupus nephritis by delaying the time to, and reducing the incidence of, renal flare by lowering anti-dsDNA (double-stranded deoxyribonucleic acid) antibody levels in Systemic Lupus Erythematosus (SLE) patients with a history of renal disease who have high-affinity antibodies to abetimus.

This withdrawal is based on the identification of additional clinical data necessary to support the Riquent application. Ongoing clinical studies of Riquent are expected to provide the necessary data; however, the data will not be available within the timeframe allowed under the Centralised Procedure.

LJP and La Jolla Limited reserve the right to make further submissions at a future date in this or other therapeutic indications(s) for Riquent.

LJP and La Jolla Limited agree for this letter to be published on the EMEA website.

Yours sincerely,